The ISN-ACT Global Trials Focus team has collected and published a new list of randomized research from nephrologists around the world for August 2020.
Each trial is reviewed in context and the risk of bias in seven key areas is assessed.
Highlight:
Allopurinol does not slow the progression of chronic kidney disease in patients with type 1 diabetes.
See the latest trials here.
Would you like to support equal access to nephrology research? Become an ISN Member
The ISN recognizes the importance of global research initiatives in advancing... read more
The “ISN Global Kidney Trials Insights: A Guide for Everyone”... read more
Nephrology has published the paper "Structures for Quality Assurance and Measurements... read more
Kidney International® NAVKIDS2: A Lesson in Matching Outcomes Measures to Interventions The... read more
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence... read more
The BMJ has published the paper, "Progress of Nations in the... read more
ISN-ACT Global Trials Focus Subgroup member Marimar Contreras Nieves summarizes the design... read more
The Nephrology Dialysis Transplantation (NDT) Supplement "Current Status of Kidney Care... read more
Rare kidney diseases (RKD) place a substantial economic burden on patients... read more
ISN-ACT Global Trials Focus editorial team member Michele Provenzano summarizes the design... read more
